Evolus Appoints New Principal Financial Officer

The latest update is out from Evolus ( (EOLS) ).

On August 1, 2025, Evolus appointed David Moatazedi as Principal Financial Officer, while continuing his role as President and CEO, without additional compensation. The company also announced the departure of Chief Marketing Officer Tomoko Yamagishi-Dressler, effective August 22, 2025, with severance benefits as per her employment agreement. Evolus reported a 4% increase in Q2 2025 net revenue to $69.4 million, driven by the successful launch of Evolysse™ and international growth, despite a decline in U.S. aesthetic procedures. The company expects to achieve meaningful profitability by Q4 2025 and aims for $700 million in total net revenue by 2028, leveraging its existing infrastructure and new product launches.

The most recent analyst rating on (EOLS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Evolus stock, see the EOLS Stock Forecast page.

Spark’s Take on EOLS Stock

According to Spark, TipRanks’ AI Analyst, EOLS is a Neutral.

Evolus faces significant financial challenges with deficits in equity and ongoing reliance on external financing. However, strategic moves such as the new credit facility and successful product launches provide a positive outlook. Technical indicators suggest a bearish trend, and valuation metrics highlight profitability concerns.

To see Spark’s full report on EOLS stock, click here.

More about Evolus

Evolus, Inc. is a global performance beauty company focused on redefining the aesthetic injectable market for the next generation of beauty consumers. The company is known for its flagship products, Jeuveau®, a neurotoxin dedicated exclusively to aesthetics, and Evolysse™, a collection of injectable hyaluronic acid (HA) gels.

Average Trading Volume: 1,066,149

Technical Sentiment Signal: Sell

Current Market Cap: $590M

Find detailed analytics on EOLS stock on TipRanks’ Stock Analysis page.